• Please log in or register to access this feature.

Coronary Artery Disease

Percutaneous coronary intervention of unprotected left main coronary artery disease

Procedural strategies and technical considerations

  1. Michael S. Lee MD, FACC1,†,
  2. Gregg W. Stone MD, FACC2,‡,
  3. Seung-Jung Park MD, FACC3,§,
  4. Paul Teirstein MD, FACC4,¶,
  5. Jeffrey Moses MD, FACC2,‖,
  6. Antonio Colombo MD, FACC5,††,
  7. David E. Kandzari MD, FACC6,‡‡,*

Article first published online: 25 JUL 2011

DOI: 10.1002/ccd.23042

Issue

Catheterization and Cardiovascular Interventions

Catheterization and Cardiovascular Interventions

Volume 79, Issue 5, pages 812–822, 1 April 2012

Additional Information

How to Cite

Lee, M. S., Stone, G. W., Park, S.-J., Teirstein, P., Moses, J., Colombo, A. and Kandzari, D. E. (2012), Percutaneous coronary intervention of unprotected left main coronary artery disease. Cathet. Cardiovasc. Intervent., 79: 812–822. doi: 10.1002/ccd.23042

Author Information

  1. 1

    University of California Los Angeles Medical Center, Los Angeles, California

  2. 2

    Columbia University Medical Center, New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York

  3. 3

    Asan Medical Center, Seoul, South Korea

  4. 4

    Scripps Clinic, La Jolla, California

  5. 5

    San Raffaele Hospital, Milan, Italy

  6. 6

    Piedmont Heart Institute, Atlanta, Georgia

  1. †

    Michael S. Lee: Honoraria from BMS, BSCI, Novartis, Merck, St. Jude Medical

  2. ‡

    Gregg Stone: Scientific advisory boards for Boston Scientific and Abbott Vascular; consultant to Medtronic, The Medicines Company, BMS-Sanofi, Eli Lilly, AstraZeneca, and Merck.

  3. §

    Seung-Jung Park: consulting fees from Cordis, lecture fees from Cordis, Medtronic, Boston Scientific, research grant from Cordis and Medtronic

  4. Paul Teirstein: consultant for Cordis, Boston Scientific, Abbott, Medtronic, and Conor; receives royalties (not on drug-eluting stents) from Boston Scientific; and owns equity in MediVas

  5. ‖

    Jeffrey Moses: Supported by Cordis, Advisory board for MIV Therapeutics, Caliber Therapeutics

  6. ††

    Antonio Colombo: None

  7. ‡‡

    David Kandzari: Medtronic, Research/grant support; Cordis, consulting

*Piedmont Heart Institute, Suite 2045, 95 Collier Road, Atlanta, Georgia 30309

  • †

    Michael S. Lee: Honoraria from BMS, BSCI, Novartis, Merck, St. Jude Medical

  • ‡

    Gregg Stone: Scientific advisory boards for Boston Scientific and Abbott Vascular; consultant to Medtronic, The Medicines Company, BMS-Sanofi, Eli Lilly, AstraZeneca, and Merck.

  • §

    Seung-Jung Park: consulting fees from Cordis, lecture fees from Cordis, Medtronic, Boston Scientific, research grant from Cordis and Medtronic

  • Paul Teirstein: consultant for Cordis, Boston Scientific, Abbott, Medtronic, and Conor; receives royalties (not on drug-eluting stents) from Boston Scientific; and owns equity in MediVas

  • ‖

    Jeffrey Moses: Supported by Cordis, Advisory board for MIV Therapeutics, Caliber Therapeutics

  • ††

    Antonio Colombo: None

  • ‡‡

    David Kandzari: Medtronic, Research/grant support; Cordis, consulting

Publication History

  1. Issue published online: 27 MAR 2012
  2. Article first published online: 25 JUL 2011
  3. Manuscript Accepted: 13 FEB 2011
  4. Manuscript Received: 25 JAN 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (870K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (870K)